October 16, 2024

Companies discussed include: Guzman y Gomez Limited (ASX:GYG)Domino’s Pizza Enterprises Limited (ASX:DMP)Incitec Pivot Limited (ASX:IPL)

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses China’s stimulus moves. Key points:A move towards more aggressive fiscal policy stimulus and property support measures should help drive a mild cyclical upswing in China’s economy.However, it’s doubtful it will be enough to reverse longer term structural problems facing China – around

AI-powered healthcare company Enlitic (ASX:ENL) has secured two major distribution agreements with Bayer Healthcare and Philips Healthcare, further cementing its presence in the global medical imaging market. The three-year partnership with Bayer will integrate Enlitic’s ENDEX platform into Bayer’s radiation dose management software. This collaboration aims to improve radiation dose monitoring at radiology sites, with

Imricor Medical Systems (ASX:IMR) has reported significant progress in its latest quarterly update, including a milestone achievement with the first MRI-guided ablation on US soil at Johns Hopkins University Hospital. This marks a critical step in the company’s efforts to secure FDA approval for its ground-breaking real-time iCMR (interventional cardiac magnetic resonance) ablation technology.  Imricor

Pro Medicus Limited (ASX:PME), a leading player in healthcare informatics, has announced a significant five-year contract extension valued at a minimum of $32 million with a prominent Australian radiology network. This extension pertains to the company’s Radiology Information System (RIS) product, Visage RIS. Dr Sam Hupert, CEO of Pro Medicus, stated, “This contract extension cements

Titomic Limited (ASX:TTT) has announced the completion of an equity placement, raising $30m to fund its expansion into the United States. The placement, priced at $0.12 per share, garnered strong support from both existing and new investors, prompting the company to increase its initial target from $25m. The funds will primarily support the establishment of

Clarity Pharmaceuticals (ASX:CU6) has reported significant developments in its SECuRE trial, which is evaluating the efficacy of 67Cu-SAR-bisPSMA for the treatment of prostate cancer. The third participant in cohort 4, a 93-year-old man with over 26 years of prostate cancer history, has completed the Dose Limiting Toxicity (DLT) period after receiving two doses of the

Chris Gosselin, CEO of Australian Fund Monitors, speaks to Nichols Chaplin, Director and Portfolio Manager at Seed Funds Management. Nicholas shares insights on APRA’s plan to phase out additional tier one bonds, which could destabilise the banking sector and impact retail investors.

To register for Friday’s webinar click here. Nyrada Inc (ASX:NYR) has successfully completed the final GLP safety study for its lead candidate, NYR-BI03. The company is now finalising its regulatory submission to the Human Ethics Research Committee (HREC), a key step toward starting its first-in-human Phase I clinical trial, expected to begin in Q4 2024.

Rita Gatt, National Lead Partner – Regulation, Security and Risk at Deloitte, discusses the revolutionary potential of quantum computing. Stef Winwood: Hi. My name is Stef Winwood from BluGlass (ASX:BLG), on behalf of Finance News Network today, and joining me today is Rita Gatt, who is a Partner at Deloitte serving as the National Lead